.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX15_Imeglimin.Imeglimin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX15_Imeglimin.Imeglimin| name: | Imeglimin |
| ATC code: | A10BX15 | route: | oral |
| n-compartments | 1 |
Imeglimin is an oral hypoglycemic agent used for the treatment of type 2 diabetes mellitus. It is a first-in-class tetrahydrotriazine compound that improves glucose-dependent insulin secretion and enhances mitochondrial function. Imeglimin is approved for use in Japan and is under investigation or regulatory review in other regions.
Pharmacokinetic parameters observed in healthy adult male and female volunteers after oral administration of imeglimin.
Chevalier, C, et al., & Fouqueray, P (2021). Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment. Clinical pharmacokinetics 60(4) 485–490. DOI:10.1007/s40262-020-00948-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33169345
Fouqueray, P, et al., & Bolze, S (2022). Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects. Clinical drug investigation 42(9) 721–732. DOI:10.1007/s40261-022-01181-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35867199
Chevalier, C, et al., & Bolze, S (2023). Imeglimin: A Clinical Pharmacology Review. Clinical pharmacokinetics 62(10) 1393–1411. DOI:10.1007/s40262-023-01301-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/37713097